Gout - Drug Pipeline Landscape, 2023

Gout - Drug Pipeline Landscape, 2023

Gout is a form of inflammatory arthritis marked by recurring flare-ups of red, painful, hot, and swollen joints brought on by the crystallization of monosodium urate monohydrate.

The underlying cause of gout is related to the high levels of uric acid crystals. This might be due to diet, genetic predisposition, or underexcretion of urate.

Symptoms of gout are sudden onset of joint swelling, joint pain, heat in the affected area, and joint redness.

Gout is diagnosed by the identification of monosodium urate crystals in synovial fluid of the affected joint by performing the following tests Joint fluid test, X-ray imaging, Ultrasound, and Dual-energy computerized tomography.

The initial treatment of gout is to reduce the symptoms of acute attacks. Tentative support is provided by applying ice several times a day. Treatment for acute treatment includes NSAIDS, colchicine, and glucocorticoids. While for prevention, there are allopurinol, febuxostat, and probenecid.

Major pharmaceutical companies are involved in the development of potential drug candidates to improve Gout treatment such as FYU-981, SEL-212A SHR4640 and others. Key players involved in the development of therapies to treat Gout are GeneScience Pharmaceuticals Co Ltd, Jiangsu HengRui, Medicine Co Ltd, LG Chem, Rigel Pharmaceuticals Inc, Shanton Pharma Co Ltd, and others. Three drugs are under late-stage Phase III clinical trials and thirteen drugs are in Phase II clinical trials and some other drugs are under Phase I, preclinical and discovery stages of development. In Dec 2022, LG Chem agreed with Innovent Biologics a representative biopharmaceutical company in China, to further enhance the business value of the global novel gout treatment project.

Report Highlights

Global Insight Service's, Gout - Drug Pipeline Landscape, 2023 report provides an overview of the Gout pipeline drugs. This report covers detailed insights on Gout drugs under development, assessment by target, mechanism of action, route of administration and molecule type. Product pipeline by companies, stage of development and key regulatory designations, deals and milestones have been presented to provide insights and thus help industry participants in their decision making. Gout pipeline report helps gain insights on drugs which are under development stage of drug development process across globally.


The research process includes extensive secondary research on public domain and other authentic sources to add or update the pipeline products information. The secondary research sources include, but are not limited to company websites, annual reports, financial reports, company pipeline chart, investor presentations and SEC filings, journals and conferences, and clinical trials registries.


The pipeline landscape report provides analysis of pipeline products based on several stages of development ranging from Discovery to Pre-Registration. The report provides a review of pipeline therapeutics by companies based on information derived from company and industry-specific sources. The pipeline report covers assessment of therapeutics by mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. Comprehensive profiles of the pipeline products with details such as company overview, development stage; molecule type, target, mechanism of action, route of administration, dosage form, regulatory designations, key deals, clinical trials, and key upcoming milestones are included.

Reasons to Buy
Helps to find and recognize significant therapeutics under development. Thorough understanding of pipeline structure and helps in developing corrective measures for pipeline projects.
Effective R&D strategies can be developed with deep knowledge of competitor information, analysis, and insights.
Plan collaborations with various industry partners that have role in some or the other stage of drug development such as contract manufacturing, co-development, contract research organization and commercialization etc.
Helps to create in-licensing and out-licensing opportunities by identifying prospective partners with attractive projects to expand business potential and scope.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.

1. Introduction
1.1 Gout - Pipeline Drugs, 2023-Coverage
2. Disease Overview - Gout
2.1 Causes
2.2 Signs and Symptoms
2.3 Diagnosis
2.4 Disease Management
3. Gout - Pipeline Drugs Development - Overview
3.1 Comparative Analysis by Stage of Development
3.2 Number of Products under Development by Companies, 2023
3.3 Products under Development by Companies, 2023
4. Assessment of Therapeutics
4.1 Assessment by Target
4.2 Assessment by Mechanism of Action
4.3 Assessment by Molecule Type
4.4 Assessment by Route of Administration
5. Drug Profiles
5.1 Clinical Stage Drugs - Phase III
5.1.1 FYU-981
5.1.2 SEL-212A
5.1.3 SHR4640
5.2 Clinical Stage Drugs - Phase II
5.2.1 ABP-671
5.2.2 ALLN-346
5.2.3 ALN-XDH
5.2.4 AR882
5.2.5 D-0120
5.2.6 DYV700
5.2.7 Genakumab
5.2.8 HP501
5.2.9 LC350189
5.2.10 OLT1177
5.2.11 SAP-001
5.2.12 SSGJ-613
5.2.13 URC102
5.3 Clinical Stage Drugs - Phase I
5.3.1 HEC93077
5.3.2 NC-2500
5.3.3 SIM0295
5.3.4 SSS11
5.3.5 THDBH130
5.3.6 UA007
5.4 Clinical Stage Drugs - IND/CTA Filed
5.4.1 THDBH131
5.5 Clinical Stage Drugs - Preclinical
5.5.1 ACQT1127
5.5.2 EC-18
5.5.3 Ery-Uricase
5.5.4 HR091506
5.5.5 NC-2700
5.5.6 Next-Gen Uncontrolled Gout
5.5.7 Novel Gout Targets
5.5.8 PB-1802
5.5.9 PRX-115
5.5.10 R835
5.5.11 THDBH150
5.5.12 THDBH151
5.5.13 THDBH160
5.5.14 THDBH161
5.5.15 TJC0434
5.5.16 WT2107
5.5.17 WTX221
5.5.18 Zunsemetinib
5.6 Clinical Stage Drugs - Discovery
5.6.1 ACQT1001
5.6.2 Drug for Gout
5.6.3 IL-1R7 Antagonist
5.6.4 Immune-evading Uricase
5.6.5 SYNB2081
5.6.6 Xanthine Oxidase Inhibitors
5.7 Clinical Stage Drugs – Unknown
5.7.1 Febuxostat
5.7.2 Rivaroxaban
6. Key Regulatory Designations
7. Key Deals
8. Key Upcoming Milestones
9. Key Companies Involved
9.1 Aclaris Therapeutics Inc
9.2 Acquist Theraputics Inc
9.3 Allena Pharmaceuticals
9.4 Alnylam Pharmaceuticals
9.5 Arthrosi Therapeutics
9.6 Cadila Healthcare Ltd
9.7 Deep Genomics Inc
9.8 Dyve Biosciences Inc
9.9 Enzy chem Lifesciences Corp
9.10 EryDel SpA
9.11 GeneScience Pharmaceuticals Co Lt
9.12 Hinova Pharmaceuticals
9.13 Horizon Pharma
9.14 IcanoMAB GmbH
9.15 InventisBio Co Ltd
9.16 Jiangsu Atom Bioscience and Pharmaceutical
9.17 Jiangsu HengRui Medicine Co Ltd
9.18 JW Pharmaceutical
9.19 LG Chem
9.20 Mochida Pharmaceutical Company Ltd
9.21 Nippon Chemiphar Co. Ltd
9.22 Olatec Therapeutics LLC
9.23 PegBio Co Ltd
9.24 Protalix BioTherapeutics Inc
9.25 Rigel Pharmaceuticals Inc
9.26 Selecta Biosciences Inc
9.27 Shanton Pharma Co Ltd
9.28 Shenyang Sunshine Pharmaceutical Co LTD
9.29 Simcere Pharmaceutical
9.30 Stealth Biologics LLC
9.31 Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd
9.32 Sunshine Lake Pharma Co Ltd
9.33 Synlogic Inc
9.34 TaiwanJ Pharmaceuticals Co Ltd
9.35 Tonghua Dongbao Pharmaceutical Co Ltd
9.36 Usynova Pharmaceuticals Ltd
9.37 Wellstat Therapeutics Corp
9.38 West Lake Biomedical Technology (Hangzhou) Co Ltd
10. Dormant Drugs
10.1 Inactive Drugs
10.2 Discontinued Drugs
11. Appendix
List of Tables
Table 1. 2 Number of Products under Development by Companies
Table 1. 3 Products under Development by Companies
Table 1. 4 Products by Targets
Table 1. 5 Products by Mechanism of Action
Table 1. 6 Products by Molecule Type
Table 1. 7 Products by Route of Administration
Table 2. 1 Clinical Trial Details - SHR4640/Jiangsu HengRui Medicine Co Ltd
Table 2. 2 Clinical Trial Details - FYU-981/Mochida Pharmaceutical Company Ltd
Table 2. 3 Clinical Trial Details - Genakumab/GeneScience Pharmaceuticals Co Ltd
Table 2. 4 Clinical Trial Details - ALN-XDH/Alnylam Pharmaceuticals
Table 2. 5 Clinical Trial Details - SSGJ-613/Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd
Table 2. 6 Clinical Trial Details - URC102/JW Pharmaceutical
Table 2. 7 Clinical Trial Details - DYV700/Dyve Biosciences Inc
Table 2. 8 Clinical Trial Details - SEL-212A/Selecta Biosciences Inc
Table 2. 9 Clinical Trial Details - HR091506 /Jiangsu HengRui Medicine Co Ltd
Table 2. 10 Clinical Trial Details - ABP-671/Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Table 2. 11 Clinical Trial Details - SAP-001/Shanton Pharma Co Ltd
Table 2. 12 Clinical Trial Details - LC350189/LG Chem
Table 2. 13 Clinical Trial Details - AR882/Arthrosi Therapeutics
Table 2. 14 Clinical Trial Details - ALLN-346/Allena Pharmaceuticals
Table 2. 15 Clinical Trial Details - SSS11/Shenyang Sunshine Pharmaceutical Co LTD
Table 2. 16 Clinical Trial Details - D-0120/InventisBio Co Ltd
Table 2. 17 Clinical Trial Details - Zunsemetinib/Aclaris Therapeutics Inc
Table 2. 18 Clinical Trial Details - HP501/Hinova Pharmaceuticals
Table 2. 19 Clinical Trial Details - OLT1177 /Olatec Therapeutics LLC
Table 2. 20 Clinical Trial Details - UA007/Usynova Pharmaceuticals Ltd
Table 2. 21 Clinical Trial Details - HEC93077/Sunshine Lake Pharma Co Ltd
Table 3. 1 Regulatory Designations
Table 4. 1 Inactive Drugs
Table 4.2 Discontinued Drugs
List of Figures
Figure 1. 1 Number of Products under Development for Gout, 2023
Figure 1. 2 Products by Top 5 Targets and Stage of Development for Gout, 2023
Figure 1. 3 Products by Top 5 Mechanism of Action for Gout, 2023
Figure 1. 4 Products by Top 5 Molecule Type for Gout, 2023
Figure 1. 5 Products by Top 5 Route of Administration for Gout, 2023

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings